Home > Financial > Can-Fite BioPharma (CANF) Could Attract Radars on Top-Line Results, CombiMatrix (CBMX) on Contract w

Can-Fite BioPharma (CANF) Could Attract Radars on Top-Line Results, CombiMatrix (CBMX) on Contract w

Added: (Mon Dec 23 2013)

Pressbox (Press Release) - Rheumatoid arthritis is an autoimmune disease in which your body’s immune system – which protects your health by attacking foreign substances like bacteria and viruses – mistakenly attacks your joints. It can affect any joint but is common in the wrist and fingers. The abnormal immune response causes inflammation that can damage joints and organs, such as the heart.

About 1.5 million people in the United States have rheumatoid arthritis (RA). Nearly three times as many women have the disease as men. In women, RA most commonly begins between ages 30 and 60. In men, it often occurs later in life.

Can-Fite BioPharma Ltd. (CANF) reported top-line results from a Phase IIb study for its proprietary-drug CF101 as a monotherapy, in patients with active rheumatoid arthritis (RA).

In the study, CF101 1 mg met all primary efficacy endpoints, showing statistically significant superiority over placebo in reducing signs and symptoms of RA as compared to the placebo.

Similar to CANF's observations in the previously reported CF101 psoriasis trials, the response of patients with RA was cumulative over time, suggesting a consistent anti-inflammatory effect of CF101. Moreover, half of the RA patients treated with CF101 showed clinically meaningful improvement.

According to CANF, CF101 was very well-tolerated with no evidence of immunosuppression. CF101 had an excellent safety profile, as has already been shown in more than 750 patients in previously reported Phase II clinical studies in autoimmune and inflammatory diseases. Additionally, all treatment-emergent adverse events were mild to moderate in intensity.

CANF's CF101 is a small molecule orally bioavailable-drug which binds with high affinity and selectivity to the A3AR, which is known to be over-expressed in inflammatory cells. The correlation between A3AR expression levels prior to treatment and patients' response to CF101 suggests that the A3AR may be utilized a predictive biomarker to be analyzed prior to patients' treatment.

CANF is focused on the development of small molecule orally bioavailable-drugs, in particular, ligands that bind to the A3 adenosine receptor. Such-drugs mediate anti-inflammatory and anti-cancer effects and the A3AR is developed as a biological predictive marker.

More about Can-Fite BioPharma Ltd. (CANF) at www.canfite.co.il

**

Crown Equity Holdings Inc. (CRWE) is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, is targeting the multi-billion dollar social networking service market.

Social media is accessible from virtually anywhere and had become an integral part of our daily lives. Social networking sites allow users to share ideas, activities, events, and interests within their individual networks.

CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States.

CRWE‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.

**

CombiMatrix Corporation (CBMX) reported that it has entered into a contractual agreement for coverage of its diagnostic laboratory services with FedMed, a national provider network and healthcare financial services organization.

FedMed, based in Gaithersburg, Maryland, has a preferred provider network that includes more than 550,000 physicians, 4,000 hospitals and 60,000 ancillary care providers nationwide. More than 40 million people have access to FedMed's preferred provider network.

The new contract with FedMed provides its members access to CBMX's suite of molecular diagnostic solutions and comprehensive clinical support specializing in prenatal, miscarriage and pediatric healthcare.

CBMX provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care -- specializing in miscarriage analysis, prenatal and pediatric healthcare. CBMX offers comprehensive testing services for the detection of genetic abnormalities at the DNA level, beyond what can be identified through traditional methodologies. CBMX performs genetic testing utilizing advanced technologies, including microarray, FISH, PCR and G-Band chromosome analyses.

More about CombiMatrix Corporation (CBMX)at www.combimatrix.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

Submitted by:Karl Matthews
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.